Selective laser photocoagulation of placental communicating vessels ❋ Unknown (2010)
The family was counseled about management options that included selective laser photocoagulation therapy for selective bipolar umbilical cord cauterization given the high likelihood of death in the recipient fetus. ❋ Unknown (2010)
Because of the progression of findings characteristic of twin-twin transfusion syndrome despite amnioreduction therapy, she was offered selective laser photocoagulation treatment. ❋ Unknown (2010)
Minimally invasive fetal surgery including fetoscopic laser photocoagulation, radio frequency ablation and/or bipolar cord coagulation, and thoracoamniotic and vesicoamniotic shunting ❋ Unknown (2010)
While selective laser photocoagulation therapy could separate the vascular communications that linked the fates of the two fetuses should one twin die, such therapy would place the donor twin at increased risk for poor outcome due to placental insufficiency given that donor twins almost inevitably have a much smaller portion of placental mass than their larger, recipient co-twin. ❋ Unknown (2010)
The only treatment that addresses the underlying cause of the disease and has been shown to reduce the neurologic morbidity of Twin-Twin Transfusion Syndrome is fetoscopic laser photocoagulation of communicating inter-twin vessels across the surface of the placenta. ❋ Unknown (2010)
Crombleholme TM, Shera D, Lee H, Johnson MP, D'Alson M, Porter F, Chyu J, SIlver R et al. A prospective, randomized, multicenter trial of amnioreduction vs selective fetoscopic laser photocoagulation for the treatment of severe twin-twin transfusion syndrome. ❋ Unknown (2010)
They would pay for retinal photocoagulation in diabetic patients but not for unrelated refraction pursuant to prescribing eyeglasses. ❋ Unknown (2008)
MicroPulse is a patented laser technology pioneered by IRIDEX which enables tissue-sparing photocoagulation therapies to treat eye diseases.
On July 27, 2011, the National Institute for Health and Clinical Excellence (NICE) issued final guidance recommending OZURDEX® (dexamethasone 0.7mg intravitreal implant in applicator) for the treatment of macular edema due to central retinal vein occlusion and also for branch retinal vein occlusion where laser photocoagulation is neither beneficial nor appropriate.
An increasing body of evidence shows that MicroPulse laser treatments can induce a therapeutic response with no detectable tissue damage and with improved visual function when compared to conventional photocoagulation treatments.
The study also collected data on a number of secondary outcome measures at one and two years, including the proportion of subjects with an improvement in vision at two years, changes in average visual acuity over time, proportion of eyes experiencing a change in the degree of retinopathy, the use of laser photocoagulation therapy, optical coherence tomography ❋ Unknown (2010)
Focal or grid photocoagulation became the standard of care for diabetic macular edema and has remained the mainstay of treatment since 1985. ❋ Unknown (2010)
(Lucentis) was added to photocoagulation laser treatment than with laser alone, according to results of a National Eye Institute-sponsored study. ❋ Unknown (2010)
Michael Bebbington, M.D., of the CFDT, reviews current therapies for this condition, noting that the scientific evidence favors selective laser photocoagulation. ❋ Unknown (2010)
Now exclusively focused in the cataract therapeutic area, the company previously developed and commercialized the PASCAL Method of retinal photocoagulation, which was acquired by Topcon Corp. in August ❋ Unknown (2010)
